FDA Fast-Tracks First Treatment for Alzheimer's Psychosis

A breakthrough therapy for hallucinations and delusions in Alzheimer's patients just earned FDA fast-track status, bringing hope to millions facing a condition with no approved treatments.

Results from ongoing trials are expected this fall.